

[redacted]

This was a single-dose randomised 2-way crossover study in 15 females who were between days 5 and 15 in their menstrual cycle. The tablet treatments contained the same actives gestodene 70 ug and ethinyloestradiol 30 ug, but differed in their formulations.

[redacted]

This was a single-dose randomised 2-way crossover study in 3 females. Neither of the treatments is intended for use in Australia, viz IV formulation containing 50 ug of gestodene and oral capsules containing 500 ug of gestodene.

[redacted]

[redacted]

This study involved IV administration of 75 ug of gestodene followed by oral doses, given in random fashion, of 25 ug, 75 ug and 125 ug of gestodene in tablets also containing 30 ug of ethinyloestradiol.

[redacted]

This was an open, randomised 3-period crossover study in 27 healthy menstruating females (24 completed all phases). Subjects were studied between days 4-6 of 3 menstrual cycles. Treatments were 2 different tablet formulations and an oral solution - all containing 50 ug gestodene / 30 ug ethinyloestradiol.

[redacted]

[redacted]

[redacted] Bioequivalence and relative bioavailability of two combination tablets of gestodene and ethinyloestradiol (70/40) relative to a combination solution, [redacted]

[redacted]

[redacted] Bioequivalence and relative bioavailability of two combination tablets of gestodene and ethinyloestradiol (100/30) with respect to a combination solution, [redacted]

[redacted]